A recent pan-cancer analysis (not including OCCC) showed an increased mutational load in ARID1A-mutated tumours [53], suggesting that ARID1A mutant OCCCs may have a higher TMB, and thus potentially respond better to anti-PD-L1 therapies. This evidence concerns the gene CD274 and neoplasm.